Aluminum and Tau in Neurofibrillary Tangles in Familial Alzheimer's Disease. 2021

Matthew John Mold, and Adam O'Farrell, and Benjamin Morris, and Christopher Exley
The Birchall Centre, Lennard-Jones Laboratories, Keele University, Keele, Staffordshire, UK.

BACKGROUND Familial Alzheimer's disease (fAD) is driven by genetic predispositions affecting the expression and metabolism of the amyloid-β protein precursor. Aluminum is a non-essential yet biologically-reactive metal implicated in the etiology of AD. Recent research has identified aluminum intricately and unequivocally associated with amyloid-β in senile plaques and, more tentatively, co-deposited with neuropil-like threads in the brains of a Colombian cohort of donors with fAD. OBJECTIVE Herein, we have assessed the co-localization of aluminum to immunolabelled phosphorylated tau to probe the potential preferential binding of aluminum to senile plaques or neurofibrillary tangles in the same Colombian kindred. METHODS Herein, we have performed phosphorylated tau-specific immunolabelling followed by aluminum-specific fluorescence microscopy of the identical brain tissue sections via a sequential labelling method. RESULTS Aluminum was co-localized with immunoreactive phosphorylated tau in the brains of donors with fAD. While aluminum was predominantly co-located to neurofibrillary tangles in the temporal cortex, aluminum was more frequently co-deposited with cortical senile plaques. CONCLUSIONS These data suggest that the co-deposition of aluminum with amyloid-β precedes that with neurofibrillary tangles. Extracellularly deposited amyloid-β may also be more immediately available to bind aluminum versus intracellular aggregates of tau. Therapeutic approaches to reduce tau have demonstrated the amelioration of its synergistic interactions with amyloid-β, ultimately reducing tau pathology and reducing neuronal loss. These data support the intricate associations of aluminum in the neuropathology of fAD, of which its subsequent reduction may further therapeutic benefits observed in ongoing clinical trials in vivo.

UI MeSH Term Description Entries

Related Publications

Matthew John Mold, and Adam O'Farrell, and Benjamin Morris, and Christopher Exley
January 1997, Neurotoxicology,
Matthew John Mold, and Adam O'Farrell, and Benjamin Morris, and Christopher Exley
January 1987, Journal of neural transmission. Supplementum,
Matthew John Mold, and Adam O'Farrell, and Benjamin Morris, and Christopher Exley
October 1998, European neurology,
Matthew John Mold, and Adam O'Farrell, and Benjamin Morris, and Christopher Exley
January 2006, Journal of Alzheimer's disease : JAD,
Matthew John Mold, and Adam O'Farrell, and Benjamin Morris, and Christopher Exley
May 2022, Nature communications,
Matthew John Mold, and Adam O'Farrell, and Benjamin Morris, and Christopher Exley
August 2003, Proceedings of the National Academy of Sciences of the United States of America,
Matthew John Mold, and Adam O'Farrell, and Benjamin Morris, and Christopher Exley
September 1989, Neuroscience letters,
Matthew John Mold, and Adam O'Farrell, and Benjamin Morris, and Christopher Exley
January 2001, Biochemical Society symposium,
Matthew John Mold, and Adam O'Farrell, and Benjamin Morris, and Christopher Exley
December 1997, Neuroreport,
Matthew John Mold, and Adam O'Farrell, and Benjamin Morris, and Christopher Exley
January 2002, Neurochemistry international,
Copied contents to your clipboard!